LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
The Neurobiology of Painting
International Review of Neurobiology
- 1st Edition, Volume 74 - April 3, 2006
- Editors: Ronald J. Bradley, F. Clifford Rose, R. Adron Harris, Peter Jenner
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 3 6 6 8 7 5 - 2
- Paperback ISBN:9 7 8 - 0 - 1 2 - 3 9 9 2 3 2 - 1
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 4 6 3 6 1 - 2
The book presents a basis for the interaction of the brain and nervous system with painting, music and literature, and a discussion of art from multiple facets – such as anatomy,… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe book presents a basis for the interaction of the brain and nervous system with painting, music and literature, and a discussion of art from multiple facets – such as anatomy, migraine, illusion and evolutionary biology. The book explores several aspects of the neurobiology of painting, including evolutionary neurobiology, sensation vs. perception, the visual brain and how the mind works, and also explores the affects of brain disorders and trauma on artist, with a concluding chapter on Frida Kahlo and the spinal cord injury that influenced her painting.
Neuroscientists, neurologists.
- No. of pages: 360
- Language: English
- Edition: 1
- Volume: 74
- Published: April 3, 2006
- Imprint: Academic Press
- Hardback ISBN: 9780123668752
- Paperback ISBN: 9780123992321
- eBook ISBN: 9780080463612
RB
Ronald J. Bradley
Affiliations and expertise
Louisiana State University Medical Center, School of Medicine, Baton Rouge, U.S.A.RH
R. Adron Harris
Affiliations and expertise
University of Texas, USAPJ
Peter Jenner
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.
Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.
Affiliations and expertise
Emeritus Professor of Pharmacology, Institute of Pharmaceutical Sciences, King’s College London, London, UKRead The Neurobiology of Painting on ScienceDirect